 Single centre, open-label, randomised study in four parallel groups of healthy volunteers: Group 1 900 mg of eslicarbazepine acetate ESL, BIA 2-093; Group 2 450 mg of S-licarbazepine plus 450 mg of R-licarbazepine; Group 3 450 mg of S-licarbazepine; Group 4 450 mg of Rlicarbazepine. In each group, the study consisted of a single-dose period Phase A followed by a repeateddose period of 7 days of duration in which the investigational product was administered once daily Phase B. The repeated-dose phase started 96 h post single-dose. 